Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016:2016:2829583.
doi: 10.1155/2016/2829583. Epub 2016 Jan 17.

Current Diagnostic and Therapeutic Aspects of Eosinophilic Myocarditis

Petr Kuchynka  1 , Tomas Palecek  1 , Martin Masek  2 , Vladimir Cerny  2 , Lukas Lambert  2 , Ivana Vitkova  3 , Ales Linhart  1
Affiliations
Review

Current Diagnostic and Therapeutic Aspects of Eosinophilic Myocarditis

Petr Kuchynka et al. Biomed Res Int. 2016.

Abstract

Eosinophilic myocarditis (EM) represents a rare form of myocardial inflammation with very heterogeneous aetiology. In developed countries, the most prevalent causes of EM are hypersensitivity or allergic reactions, as well as hematological diseases leading to eosinophilia. The disease may have a variable clinical presentation, ranging from asymptomatic forms to life-threatening conditions. Most patients with EM have marked eosinophilia in peripheral blood. Endomyocardial biopsy needs to be performed in most cases in order to establish a definitive diagnosis of EM. The therapy depends on the underlying aetiology. Immunosuppressive therapy represents the treatment mainstay in the majority of EM forms.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Cardiac magnetic resonance (short-axis) showing global subendocardial late gadolinium enhancement of the left ventricle in a patient with histologically proven eosinophilic myocarditis.
Figure 2
Figure 2
Contrast enhanced CT scan demonstrating diffuse subendocardial hypodensity of the left ventricle in a patient with histologically proven eosinophilic myocarditis.
Figure 3
Figure 3
Endomyocardial biopsy demonstrating eosinophilic myocarditis (hematoxylin-eosin, magnification 600x).
See this image and copyright information in PMC

References

    1. Oakley C. M., Olsen E. G. J. Eosinophilia and heart disease. British Heart Journal. 1977;39(3):233–237. doi: 10.1136/hrt.39.3.233. - DOI - PMC - PubMed
    1. Séguéla P. E., Iriart X., Acar P., Montaudon M., Roudaut R., Thambo J. B. Eosinophilic cardiac disease: molecular, clinical and imaging aspects. Archives of Cardiovascular Diseases. 2015;108(4):258–268. doi: 10.1016/j.acvd.2015.01.006. - DOI - PubMed
    1. Akuthota P., Weller P. F. Spectrum of eosinophilic end-organ manifestations. Immunology and Allergy Clinics of North America. 2015;35(3):403–411. doi: 10.1016/j.iac.2015.04.002. - DOI - PMC - PubMed
    1. Gotlib J. World Health Organization-defined eosinophilic disorders: 2014 update on diagnosis, risk stratification, and management. American Journal of Hematology. 2014;89(3):325–337. doi: 10.1002/ajh.23664. - DOI - PubMed
    1. Al Ali A. M., Straatman L. P., Allard M. F., Ignaszewski A. P. Eosinophilic myocarditis: case series and review of literature. Canadian Journal of Cardiology. 2006;22(14):1233–1237. doi: 10.1016/s0828-282x(06)70965-5. - DOI - PMC - PubMed

Publication types

LinkOut - more resources